Fitnib 250mg Tablet

Fitnib 250mg Tablet is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.

Fitnib 250mg Tablet can be taken with or without food, but better to have it same time every day for better results. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, rash, vomiting and weight loss. It may cause severe diarrhea, drink plenty of fluids or consult with your doctor if it bothers you. It makes you sensitive towards sunlight, hence wear protective clothing or use sunscreen while going out. In case you develop ulceration in mouth, changes in your vision, or breathing difficulties than it is better to inform the doctor. Your doctor may advise for regular monitoring of liver function while you are taking this medicine.

Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. If you have to take an antacid or any other medicine, take it at a gap of at least 2 hours after taking the cancer medicine.

• Non-small cell lung cancer

Non-small cell lung cancer
Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Fitnib 250mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Gefimipsa

• Diarrhea
• Dry skin
• Loss of appetite
• Nausea
• Rash
• Stomatitis (Inflammation of the mouth)
• Vomiting
• Weakness
• Weight loss

Take this medicine in the dose and duration as advised by your doctor. Fitnib 250mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

Fitnib 250mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

• Fitnib 250mg Tablet helps treat non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
• Take it with or without food, preferably at the same time each day.
• Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after taking this medicine.
• Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
• Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
• Inform your doctor if you develop ulceration in your mouth, changes in your vision or if you experience a worsening cough, shortness of breath, or breathing difficulties while taking this medicine.
• Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.

Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35.

Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55.

Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17.

Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 [revised 23 Apr. 2018]. [Accessed 232 Jan. 2019] (online) Available from:

Drugs.com. Gefitinib Pregnancy and Breastfeeding Warnings. [Accessed 27 Mar. 2019] (online) Available from:

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Gefitinib. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from:

Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from: